

# Expanding Therapeutic Options in De Novo Metastatic Hormone-Sensitive Prostate Cancer Overcoming Resistance to Traditional Therapies

FRIDAY, MAY 3, 2024 | 6:00 PM – 7:30 PM CT

HENRY B. GONZÁLEZ CONVENTION CENTER, 900 E MARKET ST  
SAN ANTONIO, TX | ROOM: 217A

HYBRID 

## FACULTY



### Neeraj Agarwal, MD, FASCO

Professor of Medicine  
Presidential Endowed Chair of Cancer Research  
Senior Director for Clinical Research Innovation  
Director, Center of Investigational Therapeutics  
Director, Genitourinary Oncology Program  
Huntsman Cancer Institute  
University of Utah  
Salt Lake City, Utah



### Evan Y. Yu, MD

Section Head, Medical Oncology,  
Clinical Research Division  
Fred Hutchinson Cancer Center  
Medical Director, Clinical Research Support  
Fred Hutchinson Cancer Research Consortium  
Professor of Medicine  
Division of Hematology and Oncology,  
Department of Medicine  
University of Washington School of Medicine  
Seattle, Washington



### Scott T. Tagawa, MD, MS

Professor of Medicine  
Professor of Medicine in Urology  
Weill Cornell Medicine  
New York, New York



## Register Now!

For more information and to register, visit:

[www.medscape.org/sympo/san-antonio-mhspc](http://www.medscape.org/sympo/san-antonio-mhspc)

## TARGET AUDIENCE

This activity is intended for oncologists, urologists, pathologists, and other members of the prostate cancer care team.

## LEARNING OBJECTIVES

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  - Emerging clinical data for the management of de novo mHSPC
  - Rationale associated with AKT inhibition in de novo mHSPC
  - Genomic testing considerations associated with novel therapies in de novo mHSPC

Demonstrate greater confidence in their ability to

- Incorporate emerging therapies into the management of patients with de novo mHSPC with the help of the multidisciplinary team approach

## ACCREDITATION STATEMENT

**Medscape**



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### For Physicians

Medscape, LLC designates this live activity for a maximum of 1.50 **AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### For Nurses

Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.

### For Pharmacists

Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-132-L01-P).

## AGENDA

6:00 PM

Welcome and Introductions  
Neeraj Agarwal, MD, FASCO

6:05 PM

*Building Enhanced Treatment Pathways for De Novo mHSPC*  
Evan Y. Yu, MD

6:35 PM

*Novel Pathways to Success*  
Scott T. Tagawa, MD

6:55 PM

Panel Discussion:  
*Utilizing the MDT to Operationalize Novel Therapies*  
All Faculty

7:20 PM

Closing Remarks and Audience Q&A

7:30 PM

Program Conclusion



For more information and to register, visit:

[www.medscape.org/sympo/san-antonio-mhspc](http://www.medscape.org/sympo/san-antonio-mhspc)